Document Detail

Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.
MedLine Citation:
PMID:  21978179     Owner:  NLM     Status:  MEDLINE    
PURPOSE/AIMS: This study investigates the efficacy of intravitreal bevacizumab (IVB) for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO). Subgroup analysis was performed comparing early (within 90 days of CRVO onset) and late treatment (after 90 days) as well as perfused and ischemic subgroups.
MATERIALS AND METHODS: Retrospective review of 48 consecutive eyes with CRVO treated with IVB was performed. Data collected at various time points included best corrected visual acuity (BCVA), central foveal thickness (FT) on optical coherence tomography (OCT), perfusion status on fluorescein angiography (FA), and complications.
RESULTS: Mean initial BCVA was 20/288 compared to 20/214 at 12 months (p=0.07) and 20/204 (p=0.03) at final follow-up. Initial mean central FT was 591 micrometers compared to 339 micrometers at 12 months (p=0.003). Mean follow-up was 10.5 months, and mean number of injections was 3.7. After IVB, no significant difference in BCVA gain or edema resolution on OCT was noted between the early and late treatment groups or between the perfused and ischemic subgroups.
CONCLUSIONS: IVB improves foveal thickness in eyes with CRVO, but this does not always correlate with visual recovery. No difference in efficacy was observed for IVB treatment of perfused versus ischemic CRVO or when used for early versus late treatment.
Francis Char DeCroos; Justis P Ehlers; Sandra Stinnett; Sharon Fekrat
Related Documents :
20128319 - Effect of topical applications of a novel chlorhexidine-thymol varnish formula on mutan...
2134839 - Subgingival irrigation in the maintenance phase of periodontal therapy.
19151679 - No difference in the 5-year survival rates between the resin-bonded cantilever bridge a...
20809859 - Clinical outcomes after treatment of non-contained intrabony defects with enamel matrix...
20617219 - Influence of microwave disinfection on the linear dimensional stability of complete den...
12648269 - Clinical and sem evaluation of all-ceramic chair-side cad/cam-generated partial crowns.
15337019 - Postoperative sternal dehiscence in obese patients: incidence and prevention.
8622389 - Angiographic assessment of effects of bezafibrate on progression of coronary artery dis...
22404639 - Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2011-10-06
Journal Detail:
Title:  Current eye research     Volume:  36     ISSN:  1460-2202     ISO Abbreviation:  Curr. Eye Res.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-14     Completed Date:  2012-02-28     Revised Date:  2014-11-13    
Medline Journal Info:
Nlm Unique ID:  8104312     Medline TA:  Curr Eye Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1164-70     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Dose-Response Relationship, Drug
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Intravitreal Injections
Macular Edema / diagnosis,  drug therapy*,  etiology
Middle Aged
Retinal Vein Occlusion / complications*,  diagnosis,  drug therapy
Retrospective Studies
Secondary Prevention / methods*
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assistive technology and prediction of happiness in people withpost-polio syndrome.
Next Document:  Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and s...